Efficacy of expression treatment on o-MGD(obstructive meibomian gland dysfunction)

Efficacy of expression treatment on o-MGD(obstructive meibomian gland dysfunction) - Efficacy of expression treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025159

Enrollment

Registered

2017-02-01

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obstructive meibomian gland dysfunction

Interventions

Non-expressive treatments for one month(thermal therapy, lid hygiene, levofloxacin ophthalmic suspension 1.5% eyedrop qid, Fluorometholone ophthalmic suspension 0.1% tid, hyaluronic acid sodium ophtha

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients over 20 years old meeting the Japanese diagnostic definitions of MGD in 2010 who showed the obstruction of the meibomian glands and signd the informed consent

Exclusion criteria

Exclusion criteria: Patients who have undergone LASIK or cataract surgery within one year, wear contact lens, have systemic diseases related to dry eyes, use specific medication which may induce dry eye or MGD, have eye disease other than MGD, is pregnant or lactating

Design outcomes

Primary

Measure	Time frame
Tear break up time (one month after the treatment)	—

Secondary

Measure	Time frame
Corneal and conjunctival staining score, DR-1 grade, Meibum expressibility with Shimazaki classification, Meibography	—

Countries

Japan

Contacts

Public ContactNaohiko Nakayama

Tokyo Dental College Ichikawa General Hospital Department of Ophthalmology

nnakayama@tdc.ac.jp047-322-0151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026